Pancreatic secretory trypsin inhibitor immunoreactivity detected in serum-free culture medium of human pancreatic carcinoma cell line, CAPAN-1.
Pancreatic secretory trypsin inhibitor (PSTI) immunoreactivity was detected by a radioimmunoassay in a serum-free culture medium conditioned by a human pancreatic adenocarcinoma cell line, CAPAN-1. Its apparent rate of secretion was 280 +/- 20 fg/cell/24 h, and increased in the presence of fetal bovine serum, but was not affected by a cell density at an early stage of culture. This PSTI immunoreactivity was indistinguishable from authentic human pancreatic PSTI on gel filtration, immunoblot analysis and trypsin affinity chromatography.
Ogata
N
N
Laboratory of Molecular Oncology, Nagayoshi General Hospital, Osaka, Japan.
Murata
A
A
D000230:Adenocarcinoma / Q000032:analysis / Q000378:metabolism; D002846:Chromatography, Affinity; D003470:Culture Media; D006801:Humans; D007120:Immunochemistry; D010190:Pancreatic Neoplasms / Q000032:analysis* / Q000378:metabolism; D011863:Radioimmunoassay; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000032:analysis* / Q000378:metabolism; D014361:Trypsin Inhibitors / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000032:analysis* / Q000378:metabolism
D003470:Culture Media; D014361:Trypsin Inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic